title: [Reproductive and developmental toxicity studies of S-1090, cefmatilen hydrochloride hydrate (4)--A study on oral administration during the perinatal and lactation periods in rats].
abstract: Cefmatilen hydrochloride hydrate (S-1090) was administered daily by gavage to female rats at doses of 100, 300 or 1000 mg potency/kg/day from Day 17 of pregnancy to Day 20 of lactation to assess its effects on pregnant/lactating females and on development of the offspring. In dams, loose feces/reddish brown feces, increased cecum weight, decreased weights of the heart, spleen and submaxillary gland in all the S-1090 dosing groups and a decreased weight of the thymus in the 1000 mg potency/kg dosing group were observed. However, no effects on parturition and lactation were observed in any of the dosing groups. In F1 offspring, although increased cecum weight was found at weaning in all the S-1090 dosing groups, no abnormalities in viability, physical development, sensory functions/reflexes, behavior and reproductive function were observed. No adverse effects were observed in F2 fetuses and offspring. On the basis of these results, the no observed adverse effect levels of S-1090 are estimated to be less than 100 mg potency/kg/day for maternal general toxicity, and 1000 mg potency/kg/day for maternal reproductive toxicity and for developmental and reproductive toxicity in offspring under the conditions of the present study.
authors.affiliation: Developmental Research Laboratories, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kishi
authors.forename: M
authors.initials: M
authors.lastname: Andou
authors.forename: Y
authors.initials: Y
authors.lastname: Muraoka
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: K
authors.initials: K
authors.lastname: Hara
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: R
authors.initials: R
authors.lastname: Muranaka
authors.forename: S
authors.initials: S
authors.lastname: Kanamori
authors.forename: M
authors.initials: M
authors.lastname: Hirashiba
authors.forename: H
authors.initials: H
authors.lastname: Uchida
authors.forename: M
authors.initials: M
authors.lastname: Kawai
authors.forename: K
authors.initials: K
authors.lastname: Ikeuchi
authors.forename: A
authors.initials: A
authors.lastname: Hishikawa
authors.forename: M
authors.initials: M
authors.lastname: Kaneto
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn; D001835:Body Weight / Q000187:drug effects; D002511:Cephalosporins / Q000633:toxicity*; D004435:Eating / Q000187:drug effects; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D005260:Female; D007743:Labor, Obstetric / Q000187:drug effects*; D007774:Lactation / Q000187:drug effects*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D002511:Cephalosporins; C419864:cefmatilen